1-2 of 2
Catherine Geh
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

AZD5438, a potent oral inhibitor of cyclin-dependent kinases 1, 2, and 9, leads to pharmacodynamic changes and potent antitumor effects in human tumor xenografts

Free
Kate F. Byth, Andrew Thomas, Gareth Hughes, Cheryl Forder, Alexandra McGregor, Catherine Geh, Sandra Oakes, Clive Green, Mike Walker, Nicholas Newcombe, Stephen Green, Jim Growcott, Andy Barker, Robert W. Wilkinson
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (7): 1856–1866.
https://doi.org/10.1158/1535-7163.MCT-08-0836
Published: 14 July 2009
View articletitled, AZD5438, a potent oral inhibitor of cyclin-dependent kinases 1, 2, and 9, leads to pharmacodynamic changes and potent antitumor effects in human tumor xenografts
Open the PDF for AZD5438, a potent oral inhibitor of cyclin-dependent kinases 1, 2, and 9, leads to pharmacodynamic changes and potent antitumor effects in human tumor xenografts in another window
Includes: Supplementary data
Journal Articles

The cellular phenotype of AZ703, a novel selective imidazo[1,2-a]pyridine cyclin-dependent kinase inhibitor

Free
Kate F. Byth, Catherine Geh, Cheryl L. Forder, Sandra E. Oakes, Andrew P. Thomas
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2006) 5 (3): 655–664.
https://doi.org/10.1158/1535-7163.MCT-05-0205
Published: 16 March 2006
View articletitled, The cellular phenotype of AZ703, a novel selective imidazo[1,2-a]pyridine cyclin-dependent kinase inhibitor
Open the PDF for The cellular phenotype of AZ703, a novel selective imidazo[1,2-a]pyridine cyclin-dependent kinase inhibitor in another window